Overview
Shares of IDEAYA Biosciences (NASDAQ: IDYA) rose 27% on Monday following the release of topline data from the companys Phase 2/3 registrational study, OptimUM-02. The trial evaluated darovasertib in combination with crizotinib as first-line therapy for patients with metastatic uveal melanoma who are HLA-A02:01-negative.
Primary endpoint and efficacy results
The OptimUM-02 study met its primary endpoint, demonstrating a statistically significant improvement in median progression-free survival (PFS). Patients randomized to the darovasertib plus crizotinib arm achieved a median PFS of 6.9 months compared with 3.1 months for those who received investigator choice of therapy. The reported hazard ratio was 0.42 with a 95% confidence interval of 0.30 to 0.59.
Trial population and comparator details
The study enrolled 313 patients with HLA-A02:01-negative metastatic uveal melanoma. Of those, 210 patients were assigned to the darovasertib combination, while 103 patients received investigator choice of therapy. Within the investigator choice arm, 76% of patients were treated with ipilimumab plus nivolumab and 24% received pembrolizumab.
Secondary endpoints and additional outcomes
For the secondary endpoint of overall response rate (ORR), the darovasertib combination produced a 37.1% ORR compared with 5.8% for investigator choice of therapy. According to a blinded independent central review, the darovasertib combination reduced the risk of disease progression by 58%.
Survival, safety, and next steps
Overall survival data from OptimUM-02 are not yet mature. The company reported an early trend toward improved overall survival in the darovasertib combination arm, but full conclusions await more mature follow-up. The treatment regimen was described as generally well tolerated, with a manageable safety profile. The most common Grade 3 or higher treatment-emergent adverse events included diarrhea, syncope, and hypotension.
IDEAYA intends to submit a New Drug Application to the U.S. Food and Drug Administration in the second half of 2026 seeking accelerated approval. The company also plans to present the full OptimUM-02 dataset at a major medical conference in 2026. The trial was conducted in collaboration with Servier.
Implications for markets and stakeholders
The topline readout triggered a strong market reaction reflected in the intraday share move. For investors and participants in the biotech and pharmaceutical sectors, the results will be watched closely as the program advances through regulatory review. Clinicians and patients with metastatic uveal melanoma will await the detailed data presentation later in 2026.